Related Experiment Video

Updated: Apr 18, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

Use and impact of cardiac medication during pregnancy

Annemien E van den Bosch1, Titia P E Ruys, Jolien W Roos-Hesselink

  • 1Department of Cardiology, Thorax Center, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.

Future Cardiology
|January 22, 2015
PubMed

Insights

Managing cardiovascular disease in pregnancy is crucial as it

Area of Science:

  • Obstetrics and Gynecology
  • Cardiology
  • Maternal-Fetal Medicine

Background:

  • Cardiovascular disease (CVD) is a leading cause of maternal mortality in Western countries.
  • An increasing number of women with pre-existing heart conditions are seeking pregnancy.
  • Pregnancy significantly alters maternal hemodynamics and coagulation, increasing risks for those with CVD.

Purpose of the Study:

  • To review the management strategies for cardiovascular disease during pregnancy.
  • To discuss the safety profiles of cardiac medications for both mother and fetus.
  • To provide essential information for optimal clinical decision-making.

Main Methods:

  • Literature review of existing studies on cardiovascular disease in pregnancy.
  • Analysis of hemodynamic and coagulation changes during gestation.
  • Evaluation of the teratogenic and maternal effects of common cardiac drugs.

Main Results:

  • Pregnancy imposes substantial hemodynamic stress on women with heart conditions.
  • Specific cardiac medications have varying safety profiles for fetal development.
  • Careful medication selection and monitoring are vital for reducing maternal and fetal complications.

Conclusions:

  • Effective management of cardiovascular disease in pregnancy requires a multidisciplinary approach.
  • Understanding medication safety is paramount for optimizing outcomes.
  • Continued research is needed to further refine treatment guidelines for pregnant patients with heart disease.

Keywords:
acquired heart diseaseantiarrhytmicanticoagulantantihypertensivecongenital heart diseasepregnancy

More Related Videos

Noninvasive Electrocardiography in the Perinatal Mouse04:36

Noninvasive Electrocardiography in the Perinatal Mouse

Published on: June 12, 2020

6.9K
Analysis of Electrocardiograms and Behavior in Mice from Pregnancy to Lactation Period06:40

Analysis of Electrocardiograms and Behavior in Mice from Pregnancy to Lactation Period

Published on: April 5, 2024

1.1K

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
2.0K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
545